← Back to Clinical Trials
Recruiting NCT07109180

NCT07109180 Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07109180
Status Recruiting
Phase
Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Condition Chronic Pancreatitis
Study Type INTERVENTIONAL
Enrollment 28 participants
Start Date 2025-04-16
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Robot-assisted lateral pancreaticojejunostomyOpen lateral pancreaticojejunostomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 28 participants in total. It began in 2025-04-16 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

PANACOTTA is a multicenter randomized controlled trial including patients with symptomatic chronic pancreatitis and a dilated main pancreatic duct to either robot-assisted or open lateral pancreaticojejunostomy. The PANACOTTA trial will assess the post-operative quality of recovery following robot-assisted versus open lateral pancreaticojejunostomy.

Eligibility Criteria

Inclusion Criteria: * At least 18 years old * Indication for (extended or partial) lateral pancreaticojejunostomy as agreed during multidisciplinary team meeting based on symptomatic chronic pancreatitis (i.e. morphine dependent pain or recurrent acute flares of pancreatitis, at least 3 episodes per year) and a dilated pancreatic duct of ≥ 5 mm, with a non-enlarged pancreatic head \< 40 mm * Confirmed CP, according to the M-ANNHEIM diagnostic Criteria24 * Eligible for both an robot-assisted and open approach * Obtained written informed consent Exclusion Criteria: * Suspected or confirmed current pancreatic cancer * ASA classification ≥ 4 * Other painful conditions aside from CP, with pain difficult to discriminate from CP pain * Prior pancreatic surgery * Pregnancy

Contact & Investigator

Central Contact

E. Kilinc

✉ e.kilinc@amsterdamumc.nl

📞 +31652741059

Principal Investigator

M.G. Besselink, Amsterdam UMC

PRINCIPAL INVESTIGATOR

prof. dr.

Frequently Asked Questions

Who can join the NCT07109180 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pancreatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07109180 currently recruiting?

Yes, NCT07109180 is actively recruiting participants. Contact the research team at e.kilinc@amsterdamumc.nl for enrollment information.

Where is the NCT07109180 trial being conducted?

This trial is being conducted at Amsterdam, Netherlands.

Who is sponsoring the NCT07109180 clinical trial?

NCT07109180 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The principal investigator is M.G. Besselink, Amsterdam UMC at prof. dr.. The trial plans to enroll 28 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology